IN THE UNITED STATES PATENT & TRADEMARK OFFICE

APPLICANT: Stephen Douglas Barrett, et al.

EXAMINER:

SERIAL NO.

: 10/049762

ART UNIT

FILED

: January 16, 2002

PAPER NO

FOR

: METHOD FOR TREATING CHRONIC PAIN USING MEK INHIBITORS

Statement as Provided by 37 CFR 1.97(b)

Commissioner for Patents Washington, D.C. 20231

Dear Sir:

The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of the first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

It is understood by the Applicants that this paper requires no fee; however, authorization is given to charge any necessary filing fees and any additional fees or credit any overpayment to Deposit Account 23-0455.

Respectfully submitted,

Dated: May 15, 2002

Suzanne M. Harvey

Registration No. 42,640

Warner-Lambert Company

2800 Plymouth Road

Ann Arbor, MI 48105

Telephone: (734) 622-2658 Facsimile: (734) 622-1553

Transmittal of IDS Before 1st Office Action

	Approved for use unlough 10/3 //2002. ONLO 0001-0001
	U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
	O.S. Patent and Trademark Office. C.C. DEF ATTIMETY OF COMMENTE
Under the Paperwork Reduction Act of 1995, no pers	ons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute	for form	1449A/PTO	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet of 2

Complete if Known							
Application Number 10/049762							
Filing Date	January 16, 2002						
First Named Inventor	Stephen Douglas Barrett, et al.						
Group Art Unit							
Examiner Name							
Attorney Docket Number	A0000100-01-SMH						

	U.S. PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	U.S. Patent Document Number Kind Code² (if known)		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			
		2,502,45	51	Alan August Goldberg, et al.	04/04/1950				
			,						
						· · · · · · · · · · · · · · · · · · ·			
		l	į į		1 . <u> </u>				

	FOREIGN PATENT DOCUMENTS									
Examiner Cite Initials No.of		Foreign Patent Document Kind Code ⁵ ffc e ³ Number ⁴ (<i>ji known</i>)			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶		
		EP	0316630	A1	David T. Connor, et al.	10/26/1988				
		wo	98/37881	A1	Alexander J. Bridges	09/03/1998				
		wo	99/01421	A1	Stephen D. Barrett, et al	01/14/1999				
		wo	00/35436	A2	David T. Dudley, et al.	06/22/2000				
		WO	00/41994	A1	Stephen D. Barrett, et al.	07/20/2000				
		wo	00/14505	A2	Haile Tecle, et al.	07/20/2000				
		wo	00/42002	A1	Haile Tecle	07/20/2000				
		WO	00/42003	A1	Stephen D. Barrett, et al.	07/20/2000		┼		
		\vdash			<u> </u>			+		

Examiner	Date	
Signature	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Please	type a	a plus sign	(+) insid	le this box	\rightarrow	+
--------	--------	-------------	-----------	-------------	---------------	---

PTO/SB/08B (08-00)
Please type a plus sign (+) inside this box
+

Approved for use through 10/31/2002. OMB 0651-0031
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	ite for form 1449B/F	*		Complet if Known		
				Application Number	10/049762	
INFORMATION DISCLOSURE				Filing Date	January 16, 2002	
STA	TEMENT	. RV	APPLICANT	First Named Inventor	Stephen Douglas Barrett, et al.	
317	/ I FIAI FIA I	יט	AI I LIOANI	Group Art Unit		
	(use as man	y shee	ts as necessary)	Examiner Name		
Sheet	2	of	2	Attorney Docket Number	A0000100-01-SMH	

	,	OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	_						
Examiner Initials*	Cite No.1								
•		PCT International Search Report PCT/US00/18348							
<u> </u>		N. S. DUESBERY, et al., "MEK Wars, a new front in the Battle Against Cancer", Nature Medicine, July 1999, pp 736-737, Vol. 5, No. 7							
		J. V. DUNCIA, et al., "MEK Inhibitors: The Chemistry and Biological Activity of U0126, Its Analogs, and Cyclization Products", Bioorganic & Medicinal Chemistry Letters, 1998, pp 2839-2844, No. 8							
		H. FUJIMURA, et al., "Hydroxamic Acid Derivatives", Chemical Abstracts and Indexes, January 20, 1969, Vol. 70, No. 3 Abstract Only							
		H. HIROSHI, et al., "Novel N-phenylanthranilic Acid Derivatives", Chemabs, 1968, Accession No. 1968:418858 Abstract Only							
		N. A. MOKHORT, "Dependence Between Structure, Anitinflammatory, Analgesic, and Antipyretic Actions in N-aromatic Derivatives of Anthranilic Acid", Chemabs, 1972, Accession No. 1972:121461 Abstract Only							
		RU-RONG JI, et al., "Nociceptive-specific Activation of ERK in Spinal Neurons Contributes to Pain Hypersensitivity", Nature Neuroscience, December 1999, pp 1114-1119, Vol. 2, No. 12							
		,							
	-		-						

Examiner	Date	
Signature	Consider d	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.